FDA Issues Safety Alert on Ariad’s Cancer Drug, Citing Adverse Events

October 15, 2013
The FDA issued a drug safety alert Friday for Ariad’s cancer drug Iclusig after one-fifth of patients in a postmarket clinical trial were found to have developed blood clots and narrowing of blood vessels that puts them at higher risk for heart attacks and strokes. The agency is advising all patients on Iclusig (ponatinib) to seek medical help if they experience any symptoms of a heart attack or stroke and is advising physicians to consider whether the benefits of continuing patients on the drug outweigh the risks.
Drug Industry Daily